NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-CA-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity PAR-21-025 from the NIH Guide for Grants and Contracts. The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. The long-term goal of the program is to enhance the diversity of biomedical research scientists in the Nations workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with a 3-year average of NIH Research Project Grant funding equal to or above $7.5 million total costs).
Funding Opportunity RFA-ES-21-001 from the NIH Guide for Grants and Contracts. The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding the effects of environmental exposure on peoples health.
Funding Opportunity RFA-DK-20-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2020 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org ,
Notice NOT-CA-21-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-22-003 from the NIH Guide for Grants and Contracts. The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral/social science, including market research to test user acceptability, research projects that are responding and well-coordinated to the contraceptive product being developed. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.
Funding Opportunity PAR-21-058 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.
Funding Opportunity PAR-21-056 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.
Funding Opportunity PAR-21-057 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.
Funding Opportunity PAR-21-059 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.
Funding Opportunity PAR-21-078 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.
Notice NOT-HL-20-825 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-21-160 from the NIH Guide for Grants and Contracts. The purpose of this Request for Applications (RFA) is to solicit research that will help to identify and explain the mechanisms and pathways by which interventions targeting social drivers of mental illnesses affect the mental health and functioning of children and/or adolescents (ages 5-24 years) living in World Bank designated low- and middle-income countries (LMICs) . Studies should use innovative approaches to capture as much real-world complexity as possible in identifying and elucidating mechanisms and pathways that reduce risk for mental illnesses or improve mental health in children and/or adolescents.
Notice NOT-ES-21-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-21-106 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Funding Opportunity RFA-MH-21-105 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Notice NOT-MH-21-071 from the NIH Guide for Grants and Contracts
Notice NOT-MH-21-070 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-079 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-155
Funding Opportunity PAR-21-043 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial.